Hofseth BioCare ASA Delivers Q2 2025 Financial Results
Hofseth BioCare ASA (HBC) has reported its financial results for the second quarter of 2025, highlighting significant developments and challenges faced during the period. The total operating revenues for the quarter reached NOK 68.4 million, marking a decrease from NOK 80.4 million in the same quarter last year. Net operating revenues were recorded at NOK 67.8 million, down from NOK 72.2 million over the comparable quarter in the previous year. For the first half of 2025, total operating revenue stood at NOK 129.3 million, a slight dip from NOK 132.8 million year-over-year.
Financial Insights from HBC's Performance
The company's EBITDA for Q2 was reported at a negative NOK 5.4 million, reflecting a decline from negative NOK 2 million in Q2 2024. Over the first six months of 2025, the EBITDA showed a greater loss of NOK 25.3 million compared to NOK 18.2 million last year. Interestingly, the Operational EBITDA showed a positive shift, amounting to NOK 1.3 million compared to a negative NOK 2.5 million in the same quarter last year, indicating a glimpse of operational improvement.
Cash Flow and Liquidity
HBC saw a cash and cash equivalents reduction of NOK 3.9 million during the current quarter, bringing the total to NOK 68 million as of the end of Q2 2025, which is still an improvement from NOK 25.3 million a year earlier. Moreover, with available credit lines factored in, total liquidity reached NOK 76.5 million as of June 30, 2025.
Second Quarter Highlights
Several pivotal highlights characterized HBC's success in Q2:
- Human Nutrition B2B Sales surged by an impressive 180% year-over-year to NOK 9.3 million, buoyed by strong demand from European, Chinese, and Southeast Asian markets. Product launches such as OmeGo® and ProGo® were significantly supported by scientific validation.
- NYO3® International AS launched OmegaGo® Full Spectrum Omegas in softgel format at an international event, marking a substantial milestone for HBC’s portfolio in human nutrition.
- ProGo® earned the prestigious "Panpan Cup" Food Maker Award in China and became a finalist in the NutraIngredients-USA Awards for its benefits in healthy aging.
- Brilliant Salmon Oil expanded its reach to over 25 countries, with new distributions in markets such as Italy, Ireland, Taiwan, the UAE, and Ecuador, and ongoing agreements in Japan, the Czech Republic, and Ukraine.
- Successful completion of the CalGo® bone health study demonstrated its efficacy in preventing bone loss and indicating a trend toward increased bone mass.
Plans for Research and Development
HBC is committed to advancing health research, planning a ProGo® cognitive health study aimed at understanding impacts on Alzheimer's patients. Insights from the first half of 2025 suggest a robust pipeline focused on innovative health solutions.
About Hofseth BioCare ASA
Hofseth BioCare ASA is a pioneering company from Norway dedicated to enhancing human and pet health through sustainable practices. The firm is focused on upcycling the side streams of the salmon industry, converting potential waste into valuable health-enhancing ingredients. Key products include ProGo®, a mix of bioactive peptides and collagen; OmeGo®, a comprehensive salmon oil; and CalGo®/NT-II® salmon bone powder, known for its health benefits.
Scientific Advancements at HBC
HBC places significant emphasis on scientific research, leading to pivotal academic collaborations and discoveries that showcase notable health benefits. One such finding includes ProGo®’s role in improving iron metabolism, thereby enhancing energy levels and overall health. Additionally, OmeGo® has been shown to support immune health, recovery from viral infections, and respiratory wellness amidst pollution challenges. CalGo® provides critical support for bone and joint health, catering to the needs of an aging population.
Contact Information
For further inquiries or information regarding Hofseth BioCare ASA, please reach out to:
Jon Olav Ødegård, CEO
Phone: +47 936 32 966
Email: joo@hofsethbiocare.no
Frequently Asked Questions
What key financial metrics did Hofseth BioCare report for Q2 2025?
Hofseth BioCare reported total operating revenues of NOK 68.4 million, with a negative EBITDA of NOK 5.4 million for the quarter.
How did the company's cash position change in Q2 2025?
The cash and cash equivalents decreased by NOK 3.9 million, ending at NOK 68 million, with total liquidity amounting to NOK 76.5 million.
What were some highlights from Hofseth BioCare in the second quarter?
Major highlights included a 180% increase in Human Nutrition B2B sales and notable product launches, including OmeGo® and ProGo®.
What is Hofseth BioCare's business focus?
Hofseth BioCare focuses on sustainability and health, transforming the side streams of the salmon industry into beneficial health products.
Who can I contact for more information about Hofseth BioCare?
For more information, you can contact Jon Olav Ødegård, the CEO, via email at joo@hofsethbiocare.no or call +47 936 32 966.
